Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexloxiglumide for constipation-predominant IBS
NCT00220090Phase 3Completed
- Sponsor
- Rottapharm Biotech
- Start
- Jul 2003
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Dexloxiglumide in irritable bowel syndrome (IBS) (3 arms), sponsored by Rottapharm Biotech. Primary endpoint: Time to relapse, i.e. loss of responder status, which is based on a global patient-based weekly assessment of relief and control of symptoms. Started Jul 2003; status: completed.
02
Drugs
Dexloxiglumide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00220090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220090.